These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20681062)

  • 1. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
    Karim SS; Kashuba AD; Werner L; Karim QA
    Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretrovirals for HIV prevention: translating promise into praxis.
    Mayer KH
    Lancet; 2011 Jul; 378(9787):206-8. PubMed ID: 21763922
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Battles with donors cloud Malawi's HIV prevention plan.
    Donnelly J
    Lancet; 2011 Jul; 378(9787):215-6. PubMed ID: 21770061
    [No Abstract]   [Full Text] [Related]  

  • 7. A second chance for microbicides.
    Baleta A
    Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
    [No Abstract]   [Full Text] [Related]  

  • 8. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
    Stephenson J
    JAMA; 2011 May; 305(19):1952. PubMed ID: 21586708
    [No Abstract]   [Full Text] [Related]  

  • 9. After CAPRISA 004: time to re-evaluate the HIV lexicon.
    Cates W
    Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
    [No Abstract]   [Full Text] [Related]  

  • 10. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
    Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
    Rahman SM; Vaidya NK; Zou X
    J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral prophylaxis: a defining moment in HIV control.
    Karim SS; Karim QA
    Lancet; 2011 Dec; 378(9809):e23-5. PubMed ID: 21771566
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
    Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
    AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
    Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
    Trials; 2011 Mar; 12():67. PubMed ID: 21385354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
    Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
    Trials; 2014 Dec; 15():496. PubMed ID: 25527071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir use and pregnancy among women initiating HAART.
    Maskew M; Westreich D; Firnhaber C; Sanne I
    AIDS; 2012 Nov; 26(18):2393-7. PubMed ID: 22951630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preemptive strike against HIV.
    Willyard C
    Nat Med; 2009 Feb; 15(2):126-9. PubMed ID: 19197277
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
    Williams BG; Abdool Karim SS; Karim QA; Gouws E
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should tenofovir ever be used in association with didanosine?
    Diaz RS
    Braz J Infect Dis; 2005 Dec; 9(6):452-3. PubMed ID: 16410938
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical microbicides--what's new?
    Karim QA; Baxter C; Karim SA
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S144-9. PubMed ID: 23764627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.